02418nam a22002297a 4500001001300000003000400013005001700017008004100034245017300075520146100248580011201709650003201821650002501853650002701878700002201905700002401927700003001951856005801981942000702039999001502046952012702061D0001C000056DOH20201121114613.0201121b           ||||| |||| 00| 0 eng d00aSevere acute respiratory syndrome coronavirus spike protein counteracts BST2‐mediated restriction of virus‐like particle release /cShiu‐Mei Wang [and two others]3 aBST2/tetherin, an interferon-inducible antiviral factor, can block the cellular release of various enveloped viruses. We previously reported that human coronavirus 229E (HCoV-229E) infection can alleviate the BST2 tethering of HIV-1 virions by downregulating cell surface BST2, suggesting that coronaviruses are capable of encoding anti-BST2 factors. Here we report our new finding that severe acute respiratory syndrome coronavirus (SARS-CoV) spike (S) glycoprotein, similar to Vpu, is capable of antagonizing the BST2 tethering of SARS-CoV, HCoV-229E, and HIV-1 virus-like particles via BST2 downregulation. However, unlike Vpu (which downmodulates BST2 by means of proteasomal and lysosomal degradation pathways), BST2 downregulation is apparently mediated by SARS-CoV S through the lysosomal degradation pathway only. We found that SARS-CoV S colocalized with both BST2 and reduced cell surface BST2, suggesting an association between SARS-CoV S and BST2 that targets the lysosomal degradation pathway. According to one recent report, SARS-CoV ORF7a antagonizes BST2 by interfering with BST2 glycosylation1 . Our data provide support for the proposal that SARS-CoV and other enveloped viruses are capable of evolving supplementary anti-BST2 factors in a manner that requires virus replication. Further experiments are required to determine whether the BST2-mediated restriction of authentic SARS-CoV virions is alleviated by the SARS-CoV spike protein.  aIn: J Med Virol. 2019 vol.  91 (10) page: 1743–1750.
Published online 2019 Jul 10. doi: 10.1002/jmv.25518 2a SARS Virusxclassification 2aSARS Virusxgenetics 2aSARS Virusxmetabolism1 aWang, Shiu‐Mei 1 aHuang,  Kuo‐Jung 1 aWangcorres,  Chin‐Tien   uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166632/  cCV  c1789d1789  00104070aDOHCLbDOHCLcElectronicResd2020-11-21l0oCOVID-19-000056pD0001C000056r2020-11-21 00:00:00w2020-11-21yCV